ClinicalTrials.gg
CompletedNCT00395486Updated Jul 11, 2011Results posted

ROMEO (Rosuvastatin in Metabolic syndrOme)

A Phase 4 interventional study of Rosuvastatin and Atorvastatin in Metabolic Syndrome X, sponsored by AstraZeneca. Completed at 3 sites in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-07-11.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
258
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 53 studies in Metabolic Syndrome with a site in Korea, Republic of — 4 open to participants now, 4 under way, none of them phase 3. Metabolic Syndrome · Korea, Republic of.

Enrollment
5th of 31
258 · median 67
Started
2006
with 2 others
Phase 4
11 of 53
1 open now
Registered
3rd of 53
by date

Among the 53 studies in Metabolic Syndrome with a site in Korea, Republic of, this one is the 5th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2006, is one of 11 in phase 4, and was the 3rd registered.

Metabolic Syndrome

2,118 studies on the registry are indexed under Metabolic Syndrome; 348 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

4 of the 53 studies in Metabolic Syndrome with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 232 Metabolic Syndrome studies recruiting now, 68 (29%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Metabolic Syndrome with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The primary objective of this study is to compare the effect of rosuvastatin 10mg with atorvastatin 10mg after 6 weeks of treatment in the ratio of ApoB/ApoA1 in subjects with metabolic syndrome.

03

Conditions studied

  • Metabolic Syndrome X

Browse trials for

Keywords

  • rosuvastatin
  • lipoprotein
  • metabolic syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Presence of 3 or more of the following criteria;

    • Abdominal obesity (men >90cm women >80cm)
    • Triglycerides ≥ 150 mg/dL
    • HDL-C: men \< 40 mg/dL, women \< 50 mg/dL
    • BP ≥130/≥85 mmHg or anti-hypertensive treatment
    • Fasting blood glucose ≥100 mg dL or anti-diabetic treatment
  • Elevated LDL-C ;

    • ≥130 mg/dL to \< 220 mg/dL in lipid lowering agent naive subjects
    • ≥100 mg/dL to \< 200 mg/dL in subjects who have taken a lipid lowering drug(s) within 4 weeks of visit 1.
  • Triglyceride \< 500 mg/dL
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
258 participants (actual)

Study arms

  • Experimental
    Rosuvastatin

    Drug: Rosuvastatin

  • Active comparator
    Atorvastatin

    Drug: Atorvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline in Ratio of Apolipoprotein (ApoB/ApoA1) at Week 6

    Samples for evaluation from all investigational sites will be delivered by courier to the central laboratory within 24 hours of blood being drawn. This outcome will be calculated by using the result of ApoB and ApoA1.

    Time frame: Baseline and 6 weeks

Secondary outcomes

  1. Percentage of Subjects Reaching Their LDL-C Target Goal

    Based on NCEP ATP III guideline, calculate the percentage of subjects reaching their LDL-C target goal. LDL-C target goals are \<70mg/dl, \<100mg/dl and \<130mg/dl according to their baseline conditions (presence of Coronary heart disease and risk factors and grade of Framingham 10-Year risk).

    Time frame: Baseline and 6 weeks

  2. Percentage of Subjects Reaching Their Low-Density Lipoprotein-C (LDL-C) and Non High-Density Lipoprotein-C (HDL-C) Target Goal

    Based on NCEP ATP III guideline, calculate the percentage of subjects reaching their LDL-C \& non HDL-C target goal.

    Time frame: Baseline and 6 weeks

  3. Percentage Change of Glucose Level

    Using laboratory test, mean change of glucose level was investigated.

    Time frame: Baseline and 6 weeks

  4. Percentage Change of Insulin Resistance Using HOMA-R

    HOMA-R was calculated using insulin and glucose levels derived by laboratory test. The formula is as following: HOMA-R = insulin\* glucose/22.5

    Time frame: Baseline and 6 weeks

  5. Percentage Change of Insulin Resistance Using QUICKI

    QUICKI was calculated using insulin and glucose levels derived by laboratory test. The formula is as following: QUICKI = 1/\[log(insulin) + log(glucose)\].

    Time frame: Baseline and 6 weeks

  6. Percentage Reduction of Low-Density Lipoprotein-C (LDL-C)

    Calculate the percentage reduction of LDL-C

    Time frame: Baseline and 6 weeks

  7. Percentage Change of Total Cholesterol (TC)

    Calculate the percentage change of total cholesterol level

    Time frame: Baseline and 6 weeks

  8. Percentage Change of High-Density Lipoprotein-C (HDL-C)

    Calculate the percentage change of HDL-C level

    Time frame: Baseline and 6 weeks

  9. Percentage Change of Triglycerides (TG)

    Calculate the percentage change of Triglycerides.

    Time frame: Baseline and 6 weeks

  10. Percentage Change of Apolipoprotein A1 (ApoA1)

    Calculate the percentage change of Apolipoprotein A1

    Time frame: Baseline and 6 weeks

  11. Percentage Change of Apolipoprotein B (ApoB)

    Calculate the percentage change of apolipoprotein B

    Time frame: Baseline and 6 weeks

07

Results

Posted Jun 16, 2011

Participant flow

A total of 613 subjects were enrolled in the study at 13 centres, of whom 258 were randomized to treatment with rosuvastatin (n=132) or atorvastatin (n=126). Subjects were recruited throughout South Korea from September 2006 to June 2008.

Participant flow — Overall Study
MilestoneRosuvastatinAtorvastatin
Started132126
Completed126121
Not completed65
Withdrew: Adverse event12
Withdrew: Withdrawal by subject52
Withdrew: Lost to follow-up01

Outcome measures

PrimaryPercentage Change From Baseline in Ratio of Apolipoprotein (ApoB/ApoA1) at Week 6

Samples for evaluation from all investigational sites will be delivered by courier to the central laboratory within 24 hours of blood being drawn. This outcome will be calculated by using the result of ApoB and ApoA1.

Time frame:
Baseline and 6 weeks
Reported as:
Mean · percent change
Percentage Change From Baseline in Ratio of Apolipoprotein (ApoB/ApoA1) at Week 6
percent changeRosuvastatinAtorvastatin
Percentage Change From Baseline in Ratio of Apolipoprotein (ApoB/ApoA1) at Week 6-44.40 ± 14.70-36.50 ± 14.10
SecondaryPercentage of Subjects Reaching Their LDL-C Target Goal

Based on NCEP ATP III guideline, calculate the percentage of subjects reaching their LDL-C target goal. LDL-C target goals are \<70mg/dl, \<100mg/dl and \<130mg/dl according to their baseline conditions (presence of Coronary heart disease and risk factors and grade of Framingham 10-Year risk).

Time frame:
Baseline and 6 weeks
Reported as:
Number · percentage of participants
Percentage of Subjects Reaching Their LDL-C Target Goal
percentage of participantsRosuvastatinAtorvastatin
Percentage of Subjects Reaching Their LDL-C Target Goal88.2075.40
SecondaryPercentage of Subjects Reaching Their Low-Density Lipoprotein-C (LDL-C) and Non High-Density Lipoprotein-C (HDL-C) Target Goal

Based on NCEP ATP III guideline, calculate the percentage of subjects reaching their LDL-C \& non HDL-C target goal.

Time frame:
Baseline and 6 weeks
Reported as:
Number · percentage of participants
Percentage of Subjects Reaching Their Low-Density Lipoprotein-C (LDL-C) and Non High-Density Lipoprotein-C (HDL-C) Target Goal
percentage of participantsRosuvastatinAtorvastatin
Percentage of Subjects Reaching Their Low-Density Lipoprotein-C (LDL-C) and Non High-Density Lipoprotein-C (HDL-C) Target Goal78.8066.70
SecondaryPercentage Change of Glucose Level

Using laboratory test, mean change of glucose level was investigated.

Time frame:
Baseline and 6 weeks
Reported as:
Mean · Percentage change
Percentage Change of Glucose Level
Percentage changeRosuvastatinAtorvastatin
Percentage Change of Glucose Level-0.60 ± 10.102.78 ± 13.90
SecondaryPercentage Change of Insulin Resistance Using HOMA-R

HOMA-R was calculated using insulin and glucose levels derived by laboratory test. The formula is as following: HOMA-R = insulin\* glucose/22.5

Time frame:
Baseline and 6 weeks
Reported as:
Mean · percentage change
Percentage Change of Insulin Resistance Using HOMA-R
percentage changeRosuvastatinAtorvastatin
Percentage Change of Insulin Resistance Using HOMA-R28.00 ± 95.2050.30 ± 287.50
SecondaryPercentage Change of Insulin Resistance Using QUICKI

QUICKI was calculated using insulin and glucose levels derived by laboratory test. The formula is as following: QUICKI = 1/\[log(insulin) + log(glucose)\].

Time frame:
Baseline and 6 weeks
Reported as:
Mean · percentage change
Percentage Change of Insulin Resistance Using QUICKI
percentage changeRosuvastatinAtorvastatin
Percentage Change of Insulin Resistance Using QUICKI-1.27 ± 13.90-1.03 ± 15.00
SecondaryPercentage Reduction of Low-Density Lipoprotein-C (LDL-C)

Calculate the percentage reduction of LDL-C

Time frame:
Baseline and 6 weeks
Reported as:
Mean · percentage reduction
Percentage Reduction of Low-Density Lipoprotein-C (LDL-C)
percentage reductionRosuvastatinAtorvastatin
Percentage Reduction of Low-Density Lipoprotein-C (LDL-C)-45.50 ± 15.10-37.90 ± 13.40
SecondaryPercentage Change of Total Cholesterol (TC)

Calculate the percentage change of total cholesterol level

Time frame:
Baseline and 6 weeks
Reported as:
Mean · percentage change
Percentage Change of Total Cholesterol (TC)
percentage changeRosuvastatinAtorvastatin
Percentage Change of Total Cholesterol (TC)-34.10 ± 11.20-28.80 ± 10.90
SecondaryPercentage Change of High-Density Lipoprotein-C (HDL-C)

Calculate the percentage change of HDL-C level

Time frame:
Baseline and 6 weeks
Reported as:
Mean · percentage change
Percentage Change of High-Density Lipoprotein-C (HDL-C)
percentage changeRosuvastatinAtorvastatin
Percentage Change of High-Density Lipoprotein-C (HDL-C)9.90 ± 16.408.20 ± 18.70
SecondaryPercentage Change of Triglycerides (TG)

Calculate the percentage change of Triglycerides.

Time frame:
Baseline and 6 weeks
Reported as:
Mean · percentage change
Percentage Change of Triglycerides (TG)
percentage changeRosuvastatinAtorvastatin
Percentage Change of Triglycerides (TG)-17.20 ± 33.90-15.10 ± 43.50
SecondaryPercentage Change of Apolipoprotein A1 (ApoA1)

Calculate the percentage change of Apolipoprotein A1

Time frame:
Baseline and 6 weeks
Reported as:
Mean · percentage change
Percentage Change of Apolipoprotein A1 (ApoA1)
percentage changeRosuvastatinAtorvastatin
Percentage Change of Apolipoprotein A1 (ApoA1)8.50 ± 12.404.20 ± 13.30
SecondaryPercentage Change of Apolipoprotein B (ApoB)

Calculate the percentage change of apolipoprotein B

Time frame:
Baseline and 6 weeks
Reported as:
Mean · percentage change
Percentage Change of Apolipoprotein B (ApoB)
percentage changeRosuvastatinAtorvastatin
Percentage Change of Apolipoprotein B (ApoB)-40.50 ± 14.10-34.60 ± 13.00

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rosuvastatin—0/129 (0%)0/129 (0%)
Atorvastatin—4/124 (3.2%)0/124 (0%)
Most frequent serious events
Most frequent serious events
EventRosuvastatinAtorvastatin
ArrhythmiaCardiac disorders0/1291/124
EnteritisGastrointestinal disorders0/1291/124
GastroenteritisGastrointestinal disorders0/1291/124
HaemorrhoidsGastrointestinal disorders0/1291/124
SyncopeNervous system disorders0/1291/124

Baseline characteristics

Age Continuous
Age Continuous(years)RosuvastatinAtorvastatinTotal
18 years57.5 ± 10.060.4 ± 9.058.9 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)RosuvastatinAtorvastatinTotal
Female7488162
Male583896
08

Study locations

3 sites
  • Research Site
    Pusan, Korea, Republic of
  • Research Site
    Seoul, Korea, Republic of
  • Research Site
    Suwon, Korea, Republic of
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2006, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2006
First posted
Nov 3, 2006
Start
Sep 2006
Primary completionActual
Jun 2008
CompletionActual
Jun 2008
Results first posted
Jun 16, 2011
Last update
Jul 11, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00395486
Lead sponsor
AstraZeneca
First posted
Nov 3, 2006
Start date
Sep 2006
Primary completion
Jun 2008
Completion
Jun 2008
Results posted
Jun 16, 2011
Last update
Jul 11, 2011

Study contacts

JoonWoo Bahn, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion